TriMas Corporation And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) – TriMas Corporation (TRS), Sterling Construction Company (STRL), Genmab (GMAB) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. TriMas Corporation (TRS)

22.8% sales growth and 7.83% return on equity

TriMas Corporation manufactures and provides products for consumer products, aerospace, and industrial end markets worldwide. It operates in three segments: Packaging, Aerospace, and Specialty Products. The Packaging segment offers specialty polymeric and steel closure and dispensing systems, including dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, flexible spouts, and agricultural closures; polymeric jar products; integrated dispensers; bag-in-box products; aseptic closures; industrial closures and flex spouts; and single-bodied and assembled caps and closures under the Rieke, Taplast, Affaba & Ferrari, Stolz, and Rapak brands. The Aerospace segment provides fasteners, collars, blind bolts, rivets, ducting and connectors for air management systems, and machined parts and components to original equipment manufacturers, supply chain distributors, MRO/aftermarket providers, and tier one suppliers for commercial, maintenance, repair, and operations (MRO); and military and defense aerospace applications and platforms under the Monogram Aerospace Fasteners, Allfast Fastening Systems, Mac Fasteners, RSA Engineered Products, and Martinic Engineering brands. The Specialty Products segment offers steel cylinders for use in the transportation, storage, and dispensing of compressed gases under the Norris Cylinder brand; natural gas powered wellhead engines, compressors, and replacement parts for oil and natural gas production, and other industrial and commercial markets under the Arrow brand; and spare parts for various industrial engines. The company sells its products through a direct sales force, third-party agents, and distributors. TriMas Corporation was incorporated in 1986 and is headquartered in Bloomfield Hills, Michigan.

Earnings Per Share

As for profitability, TriMas Corporation has a trailing twelve months EPS of $1.23.

PE Ratio

TriMas Corporation has a trailing twelve months price to earnings ratio of 20.5. Meaning, the purchaser of the share is investing $20.5 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.83%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

TriMas Corporation’s EBITDA is 38.61.

2. Sterling Construction Company (STRL)

18.9% sales growth and 23.61% return on equity

Sterling Construction Company, Inc., a construction company, engages in the heavy civil, specialty services, and residential construction activities primarily in the southern United States, the Rocky Mountain states, California, and Hawaii. The company undertakes various heavy civil construction projects, including highways, roads, bridges, airfields, ports, light rail, water, wastewater and storm drainage systems for the departments of transportation in various states, regional transit authorities, airport authorities, port authorities, water authorities, and railroads. It offers specialty services such as foundations for multi-family homes, parking structures, and other commercial concrete projects for blue-chip end users in the e-commerce, data center, distribution center and warehousing, energy, mixed use, and multi-family sectors. The company also undertakes concrete foundations for single-family homes. In addition, it provides surveying, clearing and grubbing, erosion control, grading, grassing, site excavation, storm drainage, sanitary sewer and water main installation, drilling and blasting, curb and gutter, paving, concrete work, and landfill services. The company was formerly known as Oakhurst Company, Inc. and changed its name to Sterling Construction Company, Inc. in November 2001. Sterling Construction Company, Inc. was founded in 1955 and is headquartered in The Woodlands, Texas.

Earnings Per Share

As for profitability, Sterling Construction Company has a trailing twelve months EPS of $3.81.

PE Ratio

Sterling Construction Company has a trailing twelve months price to earnings ratio of 22.08. Meaning, the purchaser of the share is investing $22.08 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.61%.

Sales Growth

Sterling Construction Company’s sales growth is 16.5% for the ongoing quarter and 18.9% for the next.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 2.9% and positive 28.1% for the next.

Yearly Top and Bottom Value

Sterling Construction Company’s stock is valued at $84.12 at 00:22 EST, under its 52-week high of $89.80 and way higher than its 52-week low of $34.23.

Volume

Today’s last reported volume for Sterling Construction Company is 244046 which is 29.63% below its average volume of 346818.

3. Genmab (GMAB)

17.6% sales growth and 14.78% return on equity

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Earnings Per Share

As for profitability, Genmab has a trailing twelve months EPS of $0.96.

PE Ratio

Genmab has a trailing twelve months price to earnings ratio of 30.54. Meaning, the purchaser of the share is investing $30.54 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.78%.

Moving Average

Genmab’s value is under its 50-day moving average of $29.71 and way below its 200-day moving average of $34.61.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Genmab’s EBITDA is 0.92.

4. Carrols Restaurant Group (TAST)

7.9% sales growth and 5.3% return on equity

Carrols Restaurant Group, Inc., through its subsidiaries, operates as a restaurant company in the United States. The company operates as a Burger King franchisee. As of January 3, 2021, it operated 1,009 Burger King restaurants located in 23 Northeastern, Midwestern, Southcentral, and Southeastern states; and 65 Popeyes restaurants in seven Southeastern states. The company was founded in 1960 and is headquartered in Syracuse, New York.

Earnings Per Share

As for profitability, Carrols Restaurant Group has a trailing twelve months EPS of $0.06.

PE Ratio

Carrols Restaurant Group has a trailing twelve months price to earnings ratio of 157.33. Meaning, the purchaser of the share is investing $157.33 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.3%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.2%, now sitting on 1.85B for the twelve trailing months.

Yearly Top and Bottom Value

Carrols Restaurant Group’s stock is valued at $9.44 at 00:22 EST, below its 52-week high of $9.54 and way above its 52-week low of $1.85.

Moving Average

Carrols Restaurant Group’s worth is way higher than its 50-day moving average of $8.57 and way above its 200-day moving average of $6.63.

5. JinkoSolar Holding Company Limited (JKS)

7.2% sales growth and 24.23% return on equity

JinkoSolar Holding Co., Ltd., together with its subsidiaries, engages in the design, development, production, and marketing of photovoltaic products. The company offers solar modules, silicon wafers, solar cells, recovered silicon materials, and silicon ingots. It also provides solar system integration services; and develops commercial solar power projects. The company sells its products to distributors, project developers, and system integrators; and utility, commercial, and residential customers under the JinkoSolar brand, as well as on an original equipment manufacturer basis. As of December 31, 2019, it had an integrated annual capacity of 15.0 gigawatt (GW) for silicon wafers, including 11.5 GW for mono wafers; 10.6 GW for solar cells; and 16.0 GW for solar modules. The company has operations in the People's Republic of China, the United States, Japan, Germany, the United Kingdom, Chile, South Africa, India, Mexico, Brazil, the United Arab Emirates, Italy, Spain, France, Belgium, and internationally. JinkoSolar Holding Co., Ltd. was founded in 2006 and is based in Shangrao, the People's Republic of China.

Earnings Per Share

As for profitability, JinkoSolar Holding Company Limited has a trailing twelve months EPS of $10.2.

PE Ratio

JinkoSolar Holding Company Limited has a trailing twelve months price to earnings ratio of 2.57. Meaning, the purchaser of the share is investing $2.57 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.23%.

6. Verisk Analytics (VRSK)

6.8% sales growth and 73.54% return on equity

Verisk Analytics, Inc. provides data analytics and technology solutions to the insurance markets in the United States and internationally. It offers policy language, prospective loss costs, policy writing and rating rules, and various underwriting solutions for risk selection and segmentation, pricing, and workflow optimization; property- and auto- specific rating and underwriting information solutions that allows clients to understand, quantify, underwrite, mitigate, and avoid potential loss for risks; catastrophe modeling solutions, which enables companies to identify, quantify, and plan for the financial consequences of catastrophes for use by insurers, reinsurers, intermediaries, financial institutions, and governments. The company also provides life insurance solutions for transforming current workflows in life insurance underwriting, claim insights, policy administration, unclaimed property/equity, compliance and fraud detection, and actuarial and portfolio modeling; Marketing Solutions, such as compliant, real-time decisioning, profitability, and risk assessment for inbound consumer interactions; and international underwriting and claims solutions. In addition, it offers claims insurance solutions, which provides analytics in fraud detection, compliance reporting, subrogation liability assessment, litigation, and repair cost estimation and valuation solutions; and casualty solutions, such as compliance, casualty claims decision support, and workflow automation solutions. Further, the company supplies software to the specialty insurance market. The company was founded in 1971 and is headquartered in Jersey City, New Jersey.

Earnings Per Share

As for profitability, Verisk Analytics has a trailing twelve months EPS of $5.21.

PE Ratio

Verisk Analytics has a trailing twelve months price to earnings ratio of 46.73. Meaning, the purchaser of the share is investing $46.73 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 73.54%.

7. LeMaitre Vascular (LMAT)

6.7% sales growth and 9.92% return on equity

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Earnings Per Share

As for profitability, LeMaitre Vascular has a trailing twelve months EPS of $1.22.

PE Ratio

LeMaitre Vascular has a trailing twelve months price to earnings ratio of 51.27. Meaning, the purchaser of the share is investing $51.27 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.92%.

8. Chemed Corp (CHE)

5.1% sales growth and 28.1% return on equity

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Earnings Per Share

As for profitability, Chemed Corp has a trailing twelve months EPS of $16.14.

PE Ratio

Chemed Corp has a trailing twelve months price to earnings ratio of 36.49. Meaning, the purchaser of the share is investing $36.49 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.1%.

Leave a Reply

Your email address will not be published. Required fields are marked *